Literature DB >> 15491778

Mast cells as targets of corticotropin-releasing factor and related peptides.

Theoharis C Theoharides1, Jill M Donelan, Nikoletta Papadopoulou, Jing Cao, Duraisamy Kempuraj, Pio Conti.   

Abstract

Several inflammatory skin conditions, including atopic dermatitis (AD) and psoriasis, are exacerbated by stress. Recent evidence suggests that crosstalk between mast cells, neurons and keratinocytes might be involved in such exacerbation. Mast cells are distributed widely in the skin, are present in increased numbers in AD and are located in close proximity to substance P- or neurotensin-containing neurons. Corticotropin-releasing factor (CRF), its structurally related peptide urocortin (Ucn) and their receptors are also present in the skin and their levels are increased following stress. Human mast cells synthesize and secrete both CRF and Ucn in response to immunoglobulin E receptor (FcepsilonRI) crosslinking. Mast cells also express CRF receptors, activation of which leads to the selective release of cytokines and other pro-inflammatory mediators. Thus, we propose that CRF receptor antagonists could be used together with natural molecules, such as retinol and flavonoids, to inhibit mast cell activation and provide new therapeutic options for chronic inflammatory conditions exacerbated by stress.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491778     DOI: 10.1016/j.tips.2004.09.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  83 in total

Review 1.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells.

Authors:  M Vasiadi; A Therianou; K D Alysandratos; A Katsarou-Katsari; T Petrakopoulou; A Theoharides; E Papadavid; N Stavrianeas; C Antoniou; D Kalogeromitros; T C Theoharides
Journal:  Br J Dermatol       Date:  2012-05-14       Impact factor: 9.302

3.  CRH functions as a growth factor/cytokine in the skin.

Authors:  A Slominski; B Zbytek; A Pisarchik; R M Slominski; M A Zmijewski; J Wortsman
Journal:  J Cell Physiol       Date:  2006-03       Impact factor: 6.384

4.  CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes.

Authors:  Blazej Zbytek; Andrzej T Slominski
Journal:  J Invest Dermatol       Date:  2006-10-19       Impact factor: 8.551

Review 5.  Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis.

Authors:  Stephen J Galli; Mindy Tsai
Journal:  J Dermatol Sci       Date:  2007-11-19       Impact factor: 4.563

6.  Skin as an endocrine organ: implications for its function.

Authors:  Andrzej Slominski; Jacobo Wortsman; Ralf Paus; Peter M Elias; Desmond J Tobin; Kenneth R Feingold
Journal:  Drug Discov Today Dis Mech       Date:  2008-06-01

7.  Neuroendocrinology of the skin: An overview and selective analysis.

Authors:  Michal A Zmijewski; Andrzej T Slominski
Journal:  Dermatoendocrinol       Date:  2011-01

8.  Evidence for the modulation of nociception in mice by central mast cells.

Authors:  C L Kissel; K J Kovács; A A Larson
Journal:  Eur J Pain       Date:  2017-07-19       Impact factor: 3.931

Review 9.  Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers).

Authors:  Pio Conti; Alessandro Caraffa; Gianpaolo Ronconi; Chiara M Conti; Spiros K Kritas; Filiberto Mastrangelo; Lucia Tettamanti; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

10.  On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders.

Authors:  A Slominski
Journal:  Br J Dermatol       Date:  2009-02       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.